{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:07:49Z","timestamp":1789578469728,"version":"build-2803163510"},"reference-count":79,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Lysergic acid diethylamide (LSD) is gaining renewed interest as a potential treatment for anxiety, depression, and alcohol use disorder, with clinical trials reporting significant symptom reductions and long-lasting effects. LSD modulates serotonin (5-HT2A) receptors, which, in turn, influence dysfunctional brain networks involved in emotional processing and cognition. It has also shown promise in psychedelic-assisted psychotherapy, where mystical-type experiences are linked to improved psychological well-being. This review examines LSD\u2019s pharmacokinetics, neurobiological mechanisms, and safety considerations, including cardiovascular risks, emotional vulnerability, and the potential for hallucinogen-persisting perception disorder (HPPD). Challenges such as small sample sizes, variable dosing protocols, and regulatory restrictions limit large-scale trials. Future research should focus on standardization, pharmacogenetic influences, and personalized treatment strategies to ensure its safe and effective integration into clinical practice.<\/jats:p>","DOI":"10.3390\/ph18040499","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T05:21:04Z","timestamp":1743398464000},"page":"499","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5637-8729","authenticated-orcid":false,"given":"Hossein","family":"Omidian","sequence":"first","affiliation":[{"name":"Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alborz","family":"Omidian","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Westchester Medical Center, Valhalla, NY 10595, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"key":"ref_1","unstructured":"Hofmann, A. (2013). LSD: My Problem Child, Oxford University Press."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The pharmacology of lysergic acid diethylamide: A review","volume":"14","author":"Passie","year":"2008","journal-title":"CNS Neurosci. Ther."},{"key":"ref_4","unstructured":"Grinspoon, L., and Bakalar, J.B. (1979). Psychedelic Drugs Reconsidered, Basic Books."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1192\/bjp.bp.116.194738","article-title":"Psychedelics and the science of self-experience","volume":"210","author":"Nour","year":"2017","journal-title":"Br. J. Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1021\/acs.joc.2c02564","article-title":"Six-Step Synthesis of (\u00b1)-Lysergic Acid","volume":"88","author":"Knight","year":"2023","journal-title":"J. Org. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/shm\/hkl039","article-title":"\u2018Hitting highs at rock bottom\u2019: LSD treatment for alcoholism, 1950\u20131970","volume":"19","author":"Dyck","year":"2006","journal-title":"Soc. Hist. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jhmas\/jrs050","article-title":"Efficacy and enlightenment: LSD psychotherapy and the Drug Amendments of 1962","volume":"69","author":"Oram","year":"2014","journal-title":"J. Hist. Med. Allied Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0166-4328(96)00102-7","article-title":"Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium","volume":"73","author":"Bonson","year":"1996","journal-title":"Behav. Brain Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Holze, F., Avedisian, I., Varghese, N., Eckert, A., and Liechti, M.E. (2021). Role of the 5-HT(2A) Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.711255"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.nicl.2018.03.005","article-title":"Altered network hub connectivity after acute LSD administration","volume":"18","author":"Muller","year":"2018","journal-title":"Neuroimage Clin."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1073\/pnas.1815129116","article-title":"Effective connectivity changes in LSD-induced altered states of consciousness in humans","volume":"116","author":"Preller","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41386-023-01588-2","article-title":"Dose-response relationships of LSD-induced subjective experiences in humans","volume":"48","author":"Hirschfeld","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00213-016-4453-0","article-title":"Alterations of consciousness and mystical-type experiences after acute LSD in humans","volume":"234","author":"Liechti","year":"2017","journal-title":"Psychopharmacology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41398-024-02900-4","article-title":"LSD increases sleep duration the night after microdosing","volume":"14","author":"Allen","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s40814-023-01399-8","article-title":"An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)","volume":"9","author":"Donegan","year":"2023","journal-title":"Pilot. Feasibility Stud."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/02698811211069103","article-title":"Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 microg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study","volume":"36","author":"Family","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s00213-021-05978-6","article-title":"Safety pharmacology of acute LSD administration in healthy subjects","volume":"239","author":"Holze","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.biopsych.2023.03.013","article-title":"Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial","volume":"94","author":"Murphy","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"ref_20","first-page":"7","article-title":"Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans","volume":"19","author":"Dolder","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s40262-017-0513-9","article-title":"Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects","volume":"56","author":"Dolder","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/bcp.13918","article-title":"Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects","volume":"85","author":"Holze","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bcp.2019.04.013","article-title":"Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use","volume":"164","author":"Luethi","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_24","unstructured":"(2025, March 18). 2-Oxo-3-hydroxy-LSD, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/#query=2-Oxo-3-hydroxy-LSD."},{"key":"ref_25","unstructured":"(2025, March 18). Lysergide, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/5761."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/jcla.22265","article-title":"Development and validation of an LC-MS\/MS method to quantify lysergic acid diethylamide (LSD), iso-LSD, 2-oxo-3-hydroxy-LSD, and nor-LSD and identify novel metabolites in plasma samples in a controlled clinical trial","volume":"32","author":"Dolder","year":"2018","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1039\/D4AN01361A","article-title":"A highly sensitive UHPLC-MS\/MS method for determining 15 designer LSD analogs in biological samples with application to stability studies","volume":"150","author":"Wachelko","year":"2025","journal-title":"Analyst"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1111\/add.16518","article-title":"A retrospective study of the characteristics and toxicology of cases of lysergic acid diethylamide (LSD)- and psilocybin-related death in Australia","volume":"119","author":"Darke","year":"2024","journal-title":"Addiction"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/dta.2789","article-title":"Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)","volume":"12","author":"Brandt","year":"2020","journal-title":"Drug Test. Anal."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/dta.2196","article-title":"Return of the lysergamides. Part III: Analytical characterization of N6-ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD)","volume":"9","author":"Brandt","year":"2017","journal-title":"Drug Test. Anal."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pbb.2011.12.002","article-title":"Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (\u00b1)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD)","volume":"101","author":"Schindler","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0006-8993(89)91535-7","article-title":"Common receptors for hallucinogens in rat brain: A comparative autoradiographic study using [125I]LSD and [125I]DOI, a new psychotomimetic radioligand","volume":"476","author":"McKenna","year":"1989","journal-title":"Brain Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.biopsych.2014.11.015","article-title":"Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects","volume":"78","author":"Schmid","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/dta.3691","article-title":"Analytical and behavioral characterization of 1-dodecanoyl-LSD (1DD-LSD)","volume":"17","author":"Kavanagh","year":"2025","journal-title":"Drug Test. Anal."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"117809","DOI":"10.1016\/j.neuroimage.2021.117809","article-title":"Increased sensitivity to strong perturbations in a whole-brain model of LSD","volume":"230","author":"Jobst","year":"2021","journal-title":"Neuroimage"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1021\/acsptsci.0c00099","article-title":"Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers","volume":"4","author":"Hutten","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_37","first-page":"9","article-title":"Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission","volume":"118","author":"Popic","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0006-3223(98)00069-9","article-title":"Platelet [3H]paroxetine and [3H]lysergic acid diethylamide binding in seasonal affective disorder and the effect of bright light therapy","volume":"45","author":"Smedh","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/00005072-199601000-00012","article-title":"Developmental changes in [3H]lysergic acid diethylamide ([3H]LSD) binding to serotonin receptors in the human brainstem","volume":"55","author":"Zec","year":"1996","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF00426533","article-title":"Endogenous ligands of a putative LSD-serotonin receptor in the cerebrospinal fluid: Higher level of LSD-displacing factors (LDF) in unmedicated psychotic patients","volume":"54","author":"Mehl","year":"1977","journal-title":"Psychopharmacology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/0269881120959604","article-title":"Acute subjective effects in LSD- and MDMA-assisted psychotherapy","volume":"35","author":"Schmid","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00005053-196706000-00004","article-title":"Therapeutic effects of LSD: A follow-up study","volume":"144","author":"Shagass","year":"1967","journal-title":"J. Nerv. Ment. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1097\/MJT.0000000000001726","article-title":"Psychedelic Therapy: A Primer for Primary Care Clinicians-Lysergic Acid Diethylamide (LSD)","volume":"31","author":"Beutler","year":"2024","journal-title":"Am. J. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/s41386-020-0694-z","article-title":"Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse","volume":"45","author":"Meinhardt","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s13063-024-08384-3","article-title":"LSDDEP2: Study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder","volume":"25","author":"Donegan","year":"2024","journal-title":"Trials"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0269881120940937","article-title":"A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers","volume":"35","author":"Ramaekers","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e34401","DOI":"10.1016\/j.heliyon.2024.e34401","article-title":"Clinical utility of fMRI in evaluating of LSD effect on pain-related brain networks in healthy subjects","volume":"10","author":"Faramarzi","year":"2024","journal-title":"Heliyon"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6434","DOI":"10.1017\/S0033291722002963","article-title":"Effect of lysergic acid diethylamide (LSD) on reinforcement learning in humans","volume":"53","author":"Kanen","year":"2023","journal-title":"Psychol. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Zeifman, R.J., Kettner, H., Pagni, B.A., Mallard, A., Roberts, D.E., Erritzoe, D., Ross, S., and Carhart-Harris, R.L. (2023). Co-use of MDMA with psilocybin\/LSD may buffer against challenging experiences and enhance positive experiences. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-40856-5"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s11259-022-10037-2","article-title":"Emergency vaccination of cattle against lumpy skin disease: Evaluation of safety, efficacy, and potency of MEVAC((R)) LSD vaccine containing Neethling strain","volume":"47","author":"Bazid","year":"2023","journal-title":"Vet. Res. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00213-019-05417-7","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers","volume":"237","author":"Family","year":"2020","journal-title":"Psychopharmacology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s10545-014-9680-0","article-title":"Long-term effectiveness of enzyme replacement therapy in adults with Gaucher disease: Results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10545-014-9728-1","article-title":"Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: Results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10545-014-9693-8","article-title":"Long-term effectiveness of enzyme replacement therapy in children with Gaucher disease: Results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10545-014-9717-4","article-title":"Long-term effectiveness of enzyme replacement therapy in Fabry disease: Results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/08039488.2017.1336251","article-title":"LSD treatment in Scandinavia: Emphasizing indications and short-term treatment outcomes of 151 patients in Denmark","volume":"71","author":"Larsen","year":"2017","journal-title":"Nord. J. Psychiatry"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00004850-200015010-00005","article-title":"LSD-induced hallucinogen persisting perception disorder treatment with clonidine: An open pilot study","volume":"15","author":"Lerner","year":"2000","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/ajad.12577","article-title":"Comparing triggers to visual disturbances among individuals with positive vs negative experiences of hallucinogen-persisting perception disorder (HPPD) following LSD use","volume":"26","author":"Feingold","year":"2017","journal-title":"Am. J. Addict."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1177\/02698811221099650","article-title":"Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD)","volume":"36","author":"Kopra","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/02698811231158245","article-title":"Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020","volume":"37","author":"Kopra","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamapsychiatry.2023.3867","article-title":"Use of Lysergic Acid Diethylamide by Major Depression Status","volume":"81","author":"Walsh","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"108071","DOI":"10.1016\/j.drugalcdep.2020.108071","article-title":"Trends in LSD use among US adults: 2015-2018","volume":"212","author":"Yockey","year":"2020","journal-title":"Drug Alcohol. Depend."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1523\/JNEUROSCI.1659-20.2020","article-title":"Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine","volume":"41","author":"Preller","year":"2021","journal-title":"J. Neurosci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40263-023-01008-5","article-title":"Lysergic Acid Diethylamide (LSD) for the Treatment of Anxiety Disorders: Preclinical and Clinical Evidence","volume":"37","author":"Inserra","year":"2023","journal-title":"CNS Drugs"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/archopht.1996.01100130045007","article-title":"Persistent palinopsia following ingestion of lysergic acid diethylamide (LSD)","volume":"114","author":"Kawasaki","year":"1996","journal-title":"Arch. Ophthalmol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Alper, K., Dong, B., Shah, R., Sershen, H., and Vinod, K.Y. (2018). LSD Administered as a Single Dose Reduces Alcohol Consumption in C57BL\/6J Mice. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00994"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/dta.2613","article-title":"Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD)","volume":"11","author":"Brandt","year":"2019","journal-title":"Drug Test. Anal."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"10","DOI":"10.24839\/2325-7342.JN27.3.197","article-title":"Lysergic Acid Diethylamide Produces Anxiogenic Effects in the Rat Light\/Dark Test and Elevated Plus Maze","volume":"27","author":"Conway","year":"2022","journal-title":"Psi Chi J. Psychol. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41386-023-01574-8","article-title":"The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity","volume":"48","author":"Bedford","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.4155\/fmc.15.68","article-title":"Hologram quantitative structure-activity relationship and comparative molecular interaction field analysis of aminothiazole and thiazolesulfonamide as reversible LSD1 inhibitors","volume":"7","author":"Maltarollo","year":"2015","journal-title":"Future Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jpba.2015.07.001","article-title":"Simultaneous determination of LSD and 2-oxo-3-hydroxy LSD in hair and urine by LC-MS\/MS and its application to forensic cases","volume":"115","author":"Jang","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF00442251","article-title":"Risperidone (R 64 766), a potent and complete LSD antagonist in drug discrimination by rats","volume":"97","author":"Meert","year":"1989","journal-title":"Psychopharmacology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0925-4927(01)00098-1","article-title":"EEG coherence in post-LSD visual hallucinations","volume":"107","author":"Abraham","year":"2001","journal-title":"Psychiatry Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1177\/0269881118793086","article-title":"Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016","volume":"32","author":"Leonard","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00213-023-06394-8","article-title":"Effect of LSD and music on the time-varying brain dynamics","volume":"240","author":"Adamska","year":"2023","journal-title":"Psychopharmacology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/02698811211055855","article-title":"Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a proof-of-concept study","volume":"36","author":"Hendricks","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s13063-021-05243-3","article-title":"MDLSD: Study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers","volume":"22","author":"Murphy","year":"2021","journal-title":"Trials"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/009286150804200112","article-title":"On the applications of Fisher\u2019s least significant difference (LSD) procedure in three-arm clinical trials with survival endpoints","volume":"42","author":"Liu","year":"2008","journal-title":"Drug Inf. J."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/4\/499\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:05:22Z","timestamp":1760029522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/4\/499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":79,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["ph18040499"],"URL":"https:\/\/doi.org\/10.3390\/ph18040499","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]}}}